Works by Campbell, Jordan


Results: 10
    1

    Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-42635-2
    By:
    • Rediti, Mattia;
    • Fernandez-Martinez, Aranzazu;
    • Venet, David;
    • Rothé, Françoise;
    • Hoadley, Katherine A.;
    • Parker, Joel S.;
    • Singh, Baljit;
    • Campbell, Jordan D.;
    • Ballman, Karla V.;
    • Hillman, David W.;
    • Winer, Eric P.;
    • El-Abed, Sarra;
    • Piccart, Martine;
    • Di Cosimo, Serena;
    • Symmans, William Fraser;
    • Krop, Ian E.;
    • Salgado, Roberto;
    • Loi, Sherene;
    • Pusztai, Lajos;
    • Perou, Charles M.
    Publication type:
    Article
    2
    3
    4
    5
    6

    Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance).

    Published in:
    Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2021, v. 28, n. 11, p. 5960, doi. 10.1245/s10434-021-09897-w
    By:
    • Weiss, Anna;
    • Campbell, Jordan;
    • Ballman, Karla V.;
    • Sikov, William M.;
    • Carey, Lisa A.;
    • Hwang, E. Shelley;
    • Poppe, Matthew M.;
    • Partridge, Ann H.;
    • Ollila, David W.;
    • Golshan, Mehra
    Publication type:
    Article
    7
    8
    9

    4inXchange.

    Published in:
    Canadian Theatre Review, 2024, v. 197, p. 90, doi. 10.3138/ctr.197.017
    By:
    • Bautista, Maddie;
    • Campbell, Jordan
    Publication type:
    Article
    10